Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 79, Issue 6, 2020, Pages S760-S770

  Sepriano, Alexandre ^a,b   Kerschbaumer, Andreas ^c   Smolen, Josef S ^c,d   Van Der Heijde, Désirée ^a   Dougados, Maxime ^e,f   Van Vollenhoven, Ronald ^g   McInnes, Iain B ^h   Bijlsma, Johannes W ⁱ   Burmester, Gerd R ^j   De Wit, Maarten ^k   Falzon, Louise ^l   Landewé, Robert ^m,n  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HIETZING HOSPITAL   (Austria)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f PARIS DESCARTES UNIVERSITY   (France)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k EULAR Standing Committee of People with Arthritis/Rheumatism in Europe   (Switzerland)

^l Northwell Health   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

anti TNF; DMARDs (biologic); DMARDs (synthetic); outcomes research; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; AZATHIOPRINE; BARICITINIB; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID; PENICILLAMINE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; UPADACITINIB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; DRUG;

ARTICLE; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG SAFETY; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; INTESTINE PERFORATION; MALIGNANT NEOPLASM; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; NEOPLASM; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; HERPES ZOSTER; HUMANS; INFECTIONS; INTESTINAL PERFORATION; NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNTHETIC DRUGS; VENOUS THROMBOEMBOLISM;

EID: 85079273570     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-216653     Document Type: Article

References (134)

1. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1. Ann Rheum Dis 2014;73:3-5.
2. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum dis (in revision). Annals of the Rheumatic Diseases 2019;69:964-75.
3. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: A systematic literature review Informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101-36.
4. Landewé RBM. Editorial: methotrexate saves lives: A pearl of observational research. Arthritis & Rheumatism 2013;65:307-9.
5. Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment of rheumatoid arthritis: A systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum dis 2019 (in revision). Annals of the Rheumatic Diseases 2020;79:731-46.
6. Sackett DWR, Rosenberg W, et al. Evidence-Based medicine: how to practice and teach EBM. London: Churchill Livingstone, 1997.
7. Hayden JA, Coté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37.
8. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration?s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
9. 2019. Available:file:///C:/Users/User/Downloads/bmjopen-2017-August-7-8-inlinesupplementary-material-3. pdf [Accessed 14 Dec 2019].
10. Bruce ES, Kearsley-Fleet L, Watson KD, et al. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor á: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. Rheumatology 2016;55:1336-7.
11. Carrara G, Bortoluzzi A, Sakellariou G, et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. analysis from the record linkage on rheumatic disease study of the Italian Society for rheumatology. Clin Exp Rheumatol 2019;37:60-6.
12. Cecconi M, Ranza R, Titton DC, et al. Incidence of infectious adverse events in patients with rheumatoid arthritis and spondyloarthritis on biologic Drugs-Data from the Brazilian Registry for biologics monitoring. J Clin Rheumatol 2018;25:25.
13. Cho S-K, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum 2017;47:102-7.
14. Curtis JR, Xie F, Yun H, et al. Real-World comparative risks of herpes virus infections in tofacitinib and biologic-Treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1843-7.
15. Gron KL, Arkema EV, Glintborg B, et al. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 2019;78:320-7.
16. Harrold LR, Litman HJ, Saunders KC, et al. One-Year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther 2018;20:2.
17. Lim CH, Chen H-H, Chen Y-H, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan. PLoS One 2017;12:e0178035.
18. Machado Marina Amaral de Ávila, Moura CSde, Guerra SF, et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study. Arthritis Res Ther 2018;20:60.
19. Mori S, Yoshitama T, Hidaka T, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One 2017;12:e0179179.
20. Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study. Ann Rheum Dis 2019;78:456-64.
21. Richter A, Listing J, Schneider M, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667-73.
22. Rutherford AI, Patarata E, Subesinghe S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Rheumatology 2018;57:997-1001.
23. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-Treated patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2018;17:annrheumdis-2017-212825-2010
24. Silva-Fernández L, De Cock D, Lunt M, et al. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Rheumatology 2018;57:1533-40.
25. Zamora-L egoff JA, Krause ML, Crowson CS, et al. Risk of serious infection in patients with rheumatoid arthritis-Associated interstitial lung disease. Clin Rheumatol 2016;35:2585-9.
26. Kim SC, Schneeweiss S, Liu J, et al. Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: A cohort study. Arthritis Rheumatol 2016;68:2106-13.
27. Lange E, Blizzard L, Venn A, et al. Disease-Modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: A retrospective cohort study. Rheumatology 2016;55:1594-600.
28. Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 2017;76:386-91.
29. Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2017;76:497-503.
30. Silva-Fernández L, Lunt M, Kearsley-Fleet L, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for rheumatology biologics Register-Rheumatoid arthritis. Rheumatology 2016;55:2033-9.
31. Wadström H, Frisell T, Askling J, et al. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. JAMA Intern Med 2017;177:1605-12.
32. Wadström H, Frisell T, Sparén P, et al. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis 2016;75:1272-8.
33. Desai RJ, Pawar A, Weinblatt ME, et al. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: An observational cohort study. Arthritis Rheumatol 2019;71:892-900.
34. Generali E, Carrara G, Kallikourdis M, et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int 2019;39:239-43.
35. Herrinton LJ, Ray GT, Curtis JR, et al. An observational study of cardiovascular risks associated with rheumatoid arthritis therapies: A comparison of two analytical approaches. Perm 2018;22:19.
36. Jin Y, Kang EH, Brill G, et al. Cardiovascular (cv) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline cv disease. J Rheumatol 2018;45:1240-8.
37. Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A Multi-Database cohort study. Arthritis Rheumatol 2017;69:1154-64.
38. Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum 2018;48:399-405.
39. Low ASL, Symmons DPM, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:654-60.
40. Meissner Y, Richter A, Manger B, et al. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German rabbit cohort. Ann Rheum Dis 2017;76:1583-90.
41. Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813-8.
42. Monemi S, Berber E, Sarsour K, et al. Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatol Ther 2016;3:337-52.
43. Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2017;76:504-10.
44. Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016;68:2612-7.
45. Brodszky V, Bíró A, Szekanecz Z, et al. Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEcon 2017;9:139-47.
46. Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis-The answer cohort study. PLoS One 2018;13:e0194130.
47. Gottenberg J-E , Morel J, Perrodeau E, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 2019;364:l67.
48. Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2018;36:29-35.
49. Narongroeknawin P, Chevaisrakul P, Kasitanon N, et al. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai rheumatic disease prior authorization registry. Int J Rheum Dis 2018;21:170-8.
50. Jani M, Dixon WG, Kersley-Fleet L, et al. Drug-S pecific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open 2017;3:e000314.
51. Yun H, Xie F, Beyl RN, et al. Risk of hypersensitivity to biologic agents among Medicare patients with rheumatoid arthritis. Arthritis Care Res 2017;69:1526-34.
52. Apsangikar P, Chaudhry S, Naik M, et al. A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate. Indian J Rheumatol 2018;13:84-9.
53. Bae S-C, Kim J, Choe J-Y, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: The HERA study. Ann Rheum Dis 2017;76:65-71.
54. Choe J-Y, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing Sb2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:58-64.
55. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017;76:1679-87.
56. Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis 2018;77:914-21.
57. Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther 2018;20:155.
58. Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis Res Ther 2018;20:178.
59. Jamshidi A, Gharibdoost F, Vojdanian M, et al. A phase III, randomized, two-Armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther 2017;19:168.
60. Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016;19:1157-68.
61. Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis 2018;77:488-94.
62. Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-To-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open 2018;4:e000757.
63. Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: A randomized controlled phase 3 trial. MAbs 2018;10:934-43.
64. Smolen JS, Choe J-Y, Prodanovic N, et al. Comparing biosimilar Sb2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology 2017;56:1771-9.
65. Smolen JS, Choe J-Y, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar Sb2 compared with continuing reference infliximab and Sb2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis 2018;77:234-40.
66. Smolen JS, Cohen SB, Tony H-P, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2017;76:1598-602.
67. Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab Biosimilar) in patients with rheumatoid arthritis: Fifty-Two-Week phase III randomized study results. Arthritis Rheumatol 2018;70:832-40.
68. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab Biosimilar, versus reference adalimumab in patients with moderate-To-severe rheumatoid arthritis. Arthritis Rheumatol 2018;70:40-8.
69. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.
70. Emery P, Vencovský J, Sylwestrzak A, et al. Long-Term efficacy and safety in patients with rheumatoid arthritis continuing on Sb4 or switching from reference etanercept to Sb4. Ann Rheum Dis 2017;76:1986-91.
71. Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol 2017;27:237-45.
72. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
73. Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): A randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. The Lancet 2017;389:1206-17.
74. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (monarch): A randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017;76:840-7.
75. Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017;76:1020-30.
76. Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor á monoclonal antibody: long-Term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol 2018;70:679-89.
77. Damjanov N, Tlustochowicz M, Aelion J, et al. Safety and efficacy of SBI-087, a subcutaneous agent for B cell depletion, in patients with active rheumatoid arthritis: results from a phase II randomized, double-blind, placebo-controlled study. J Rheumatol 2016;43:2094-100.
78. Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology 2019;58:849-58.
79. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 2017;69:277-90.
80. Genovese MC, Braun DK, Erickson JS, et al. Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in Biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol 2016;43:289-97.
81. Genovese MC, van Adelsberg J, Fan C, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology 2018;57:1423-31.
82. Genovese MC, Weinblatt ME, Aelion JA, et al. ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: A randomized, double-blind study. Arthritis Rheumatol 2018;70:1710-20.
83. Mease PJ, Jeka S, Jaller JJ, et al. CNTO6785, a fully human Antiinterleukin 17 monoclonal antibody, in patients with rheumatoid arthritis with inadequate response to methotrexate: A randomized, placebo-controlled, phase II, dose-ranging study. J Rheumatol 2018;45:22-31.
84. Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis 2017;76:831-9.
85. Takeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-To-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.[Erratum appears in Mod Rheumatol. 2018 Sep;28(5):911-912; PMID: 29869893]. Mod Rheumatol 2016;26:15-23.
86. Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: The phase III SIRROUND-D study. Ann Rheum Dis 2017;76:2001-8.
87. Takeuchi T, Yamanaka H, Harigai M, et al. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Res Ther 2018;20:42.
88. Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): A randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis 2018;77:658-66.
89. van Vollenhoven RF, Keystone EC, Strand V, et al. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Ann Rheum Dis 2018;77:495-9.
90. Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase IIb study of Mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol 2018;70:49-59.
91. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NE XT): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2018;391:2503-12.
92. Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
93. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): A phase 3b/4, double-blind, head-To-head, randomised controlled trial. The Lancet 2017;390:457-68.
94. Taylor PC, Krogulec M, Dudek A, et al. Rheumatoid arthritis oral abstractsO01. efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: summary results from the 52-week phase 3 RA-Beam Study. Rheumatology 2017;56:ii26-9.
95. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506-17.
96. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. The Lancet 2018;391:2513-24.
97. Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-To-severe rheumatoid arthritis. Arthritis Rheumatol 2017;69:932-42.
98. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
99. Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:46-55.
100. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (Darwin 2). Ann Rheum Dis 2017;76:1009-19.
101. Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of Baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14-21.
102. Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-To-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 2017;69:709-19.
103. Li Z-G, Liu Y, Xu H-J, et al. Efficacy and safety of tofacitinib in Chinese patients with rheumatoid arthritis. Chin Med J 2018;131:2683-92.
104. Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 2016;75:1057-64.
105. Tanaka Y, Ishii T, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Mod Rheumatol 2018;28:20-9.
106. van der Heijde D, Dougados M, Chen Y-C, et al. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open 2018;4:e000662.
107. Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Darwin 1). Ann Rheum Dis 2017;76:998-1008.
108. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-Term extension study. Arthritis Res Ther 2016;18:34.
109. Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2019;78:171-8.
110. Tanaka Y, Sugiyama N, Toyoizumi S, et al. Modified-versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study. Rheumatology 2019;58:70-9.
111. Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol 2019;71:878-91.
112. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis & Rheumatology 2017;69:1960-8.
113. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: A randomized phase II trial. Arthritis Rheumatol 2017;69:1969-77.
114. Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate. Arthritis Care Res 2019.
115. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39-52.
116. Winthrop KL. Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;13:320.
117. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.
118. Cohen SB, Tanaka Y, Mariette X, et al. Long-Term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253-62.
119. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology 2019;58:i34-42.
120. Genovese MC SJ, Takeuchi T, et al. Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis Abstract#511). Arthritis rheumatol 2017;69:Abstract 511.
121. Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial. Arthritis rheumatol 2019.
122. Arthritis Advisory Committee Meeting. FDA Briefing document, 2017. Available: https://www. fda. gov/media/106325/download
123. Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis. Arthritis rheumatol 2019.
124. European Medicines Agency (EMA). Xeljanz to be used with caution for all patients at high risk of blood clots, 2019EMA/584781/2019. Available: https://www ema europa eu/en/documents/referral/xeljanz-Article-20-procedure-xeljanzbe-used-caution-All-patients-high-risk-blood-clots-en pdf [Accessed last accessed December 14, 2019].
125. Pfizer. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis, 2019. Available: https://clinicaltrials. gov/ct2/show/NCT02092467? term= study+ A3921133& draw= 1& rank=1 [Accessed 14 Dec 2019].
126. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf 2018;41:645-53.
127. European Medicines Agency. Olumiant, 2019. Available: https://www. ema. europa. eu/en/documents/procedural-steps-After/olumiant-epar-procedural-stepstaken-scientific-information-After-Authorisation-en. pdf [Accessed 24 Jun 2019].
128. Drugs. com. Fda Advisory Committee recommends the approval of Baricitinib 2mg, but not 4mg, for the treatment of Moderately-To-S everely active rheumatoid arthritis, 2019. Available: https://www. drugs. com/nda/baricitinib-180423. html [Accessed 14 Dec 2019].
129. US Food and Drug Administration-Center for Drug Evaluation and Research. Statistical Review-Clinical Studies-Olumiant (baricitinib), 2019. Available: https://www accessdata fda gov/drugsatfda-docs/nda/2018/207924Orig1s000StatR pdf [Accessed 14 Dec 2019].
130. Chester Wasko M, Dasgupta A, Ilse Sears G, et al. Prednisone use and risk of mortality in patients with rheumatoid arthritis: moderation by use of disease-modifying antirheumatic drugs. Arthritis Care Res 2016;68:706-10.
131. Movahedi M, Costello R, Lunt M, et al. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: A retrospective cohort study. Eur J Epidemiol 2016;31:1045-55.
132. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810.
133. Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905-13.
134. GOV.UK. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation, 2019. Available: https://www. gov. uk/drug-safetyupdate/tocilizumab-roactemra-rare-risk-of-serious-liver-injury-including-casesrequiring-Transplantation [Accessed 29 Jul 2019].